[go: up one dir, main page]

EG24361A - 4-pyrimiding1-n-acy1.l.phenlalanines - Google Patents

4-pyrimiding1-n-acy1.l.phenlalanines

Info

Publication number
EG24361A
EG24361A EG20001502A EG20001502A EG24361A EG 24361 A EG24361 A EG 24361A EG 20001502 A EG20001502 A EG 20001502A EG 20001502 A EG20001502 A EG 20001502A EG 24361 A EG24361 A EG 24361A
Authority
EG
Egypt
Prior art keywords
phenlalanines
acy1
Prior art date
Application number
EG20001502A
Other languages
English (en)
Inventor
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of EG24361A publication Critical patent/EG24361A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EG20001502A 1999-12-06 2000-12-03 4-pyrimiding1-n-acy1.l.phenlalanines EG24361A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16908999P 1999-12-06 1999-12-06

Publications (1)

Publication Number Publication Date
EG24361A true EG24361A (en) 2009-03-04

Family

ID=22614222

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20001502A EG24361A (en) 1999-12-06 2000-12-03 4-pyrimiding1-n-acy1.l.phenlalanines

Country Status (35)

Country Link
EP (1) EP1237878B1 (xx)
JP (1) JP3824935B2 (xx)
KR (1) KR100522344B1 (xx)
CN (1) CN1218943C (xx)
AR (1) AR034401A1 (xx)
AT (1) ATE357433T1 (xx)
AU (1) AU783348B2 (xx)
BR (1) BR0016195A (xx)
CA (1) CA2392570C (xx)
CO (1) CO5080772A1 (xx)
CY (1) CY1106626T1 (xx)
CZ (1) CZ303435B6 (xx)
DE (1) DE60034061T2 (xx)
DK (1) DK1237878T3 (xx)
EG (1) EG24361A (xx)
ES (1) ES2282162T3 (xx)
HK (1) HK1054384B (xx)
HR (1) HRP20020468B1 (xx)
HU (1) HU229105B1 (xx)
IL (2) IL149617A0 (xx)
JO (1) JO2283B1 (xx)
MA (1) MA26850A1 (xx)
MX (1) MXPA02005564A (xx)
MY (1) MY126972A (xx)
NO (1) NO322866B1 (xx)
NZ (1) NZ518828A (xx)
PE (1) PE20010961A1 (xx)
PL (1) PL207160B1 (xx)
PT (1) PT1237878E (xx)
RS (1) RS50371B (xx)
RU (1) RU2266901C2 (xx)
SI (1) SI1237878T1 (xx)
TW (1) TWI256387B (xx)
WO (1) WO2001042225A2 (xx)
ZA (1) ZA200203533B (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
JP3440469B2 (ja) * 2000-08-18 2003-08-25 味の素株式会社 新規フェニルアラニン誘導体
AR033765A1 (es) * 2001-05-22 2004-01-07 Syngenta Participations Ag Procedimiento para la preparacion de derivados 3-alquil-3h-isobenzofuran-1-ona 7-sustituidos.
EP1454898A4 (en) * 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
KR101194176B1 (ko) 2003-12-22 2012-10-24 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
DE602005014364D1 (de) * 2004-08-16 2009-06-18 Merck & Co Inc Vla-4-antagonisten
JP4784224B2 (ja) 2004-09-24 2011-10-05 味の素株式会社 糖鎖転移方法および糖鎖転移酵素
WO2007060408A2 (en) * 2005-11-23 2007-05-31 Astrazeneca Ab L-phenylalanine derivatives and their use as integrin antagonists
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
WO2007091046A1 (en) * 2006-02-09 2007-08-16 Astrazeneca Ab Chemical compounds
AU2007262147B2 (en) * 2006-06-19 2012-08-16 Toray Industries, Inc. Therapeutic or prophylactic agent for multiple sclerosis
IN2012DN05113A (xx) 2007-09-17 2015-10-23 Abbott Lab
WO2009039134A1 (en) 2007-09-17 2009-03-26 Abbott Laboratories Anti-infective pyrimidines and uses thereof
WO2009039135A1 (en) 2007-09-17 2009-03-26 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
EP2382222B1 (en) * 2008-12-22 2013-05-01 Icl-ip America Inc. Water miscible solvent based process for purifying a bisphosphate
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
US8841487B2 (en) 2010-07-16 2014-09-23 Abbvie Inc. Phosphine ligands for catalytic reactions
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
CR20180412A (es) 2010-07-16 2018-11-01 Abbvie Ireland Unlimited Co Proceso para preparar compuestos antivirales
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
BR112014013135A2 (pt) * 2012-01-27 2017-12-05 Hoffmann La Roche composto, composição farmacêutica, método para o tratamento da inflamação, uso de um composto e invenção
US9447035B2 (en) * 2012-01-27 2016-09-20 Hoffmann-La Roche Inc. Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
BR112016009515B1 (pt) * 2013-10-29 2022-05-03 EA Pharma Co., Ltd Derivado de sulfonamida, composição farmacêutica, agente terapêutico ou um agente preventivo para doença inflamatória, e, inibidor de integrina a4ß7
EP3268369A4 (en) 2015-03-10 2018-08-08 The Regents of The University of California Anti-alphavbeta1 integrin inhibitors and methods of use
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH516578A (de) * 1967-11-02 1971-12-15 Bayer Ag Verfahren zur Herstellung von heterocyclische Acylaminogruppen enthaltenden Arylsulfonylharnstoffen mit blutdrucksenkender Wirkung
ATE318841T1 (de) * 1997-05-29 2006-03-15 Merck & Co Inc Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
DK1005445T3 (da) * 1997-08-22 2004-10-04 Hoffmann La Roche N-alkanoylphenylaninderivater
CN1276785A (zh) * 1997-08-22 2000-12-13 霍夫曼-拉罗奇有限公司 N－烷酰基苯丙氨酸衍生物
JP2002535304A (ja) * 1999-01-22 2002-10-22 エラン ファーマシューティカルズ，インコーポレイテッド Ｖａｌ−４により媒介される白血球接着を阻害する多環式化合物

Also Published As

Publication number Publication date
DK1237878T3 (da) 2007-07-30
WO2001042225A2 (en) 2001-06-14
KR100522344B1 (ko) 2005-10-20
NO20022633L (no) 2002-06-04
ZA200203533B (en) 2003-08-04
AU2669601A (en) 2001-06-18
JP3824935B2 (ja) 2006-09-20
HU229105B1 (en) 2013-07-29
AU783348B2 (en) 2005-10-20
PE20010961A1 (es) 2001-09-26
MXPA02005564A (es) 2002-09-02
AR034401A1 (es) 2004-02-25
DE60034061T2 (de) 2007-12-13
HUP0204081A3 (en) 2003-07-28
MA26850A1 (fr) 2004-12-20
HRP20020468A2 (en) 2004-04-30
DE60034061D1 (de) 2007-05-03
CY1106626T1 (el) 2012-01-25
HK1054384A1 (en) 2003-11-28
JP2003516396A (ja) 2003-05-13
HUP0204081A2 (en) 2003-05-28
RU2266901C2 (ru) 2005-12-27
NO322866B1 (no) 2006-12-18
TWI256387B (en) 2006-06-11
ATE357433T1 (de) 2007-04-15
CZ303435B6 (cs) 2012-09-12
JO2283B1 (en) 2005-09-12
CA2392570A1 (en) 2001-06-14
BR0016195A (pt) 2002-08-13
CN1407972A (zh) 2003-04-02
HK1054384B (zh) 2005-12-09
CZ20022351A3 (cs) 2003-04-16
IL149617A (en) 2007-10-31
IL149617A0 (en) 2002-11-10
RS50371B (sr) 2009-11-10
CO5080772A1 (es) 2001-09-25
YU40402A (xx) 2005-03-15
PL207160B1 (pl) 2010-11-30
CN1218943C (zh) 2005-09-14
PL357601A1 (en) 2004-07-26
WO2001042225A3 (en) 2002-02-21
NZ518828A (en) 2004-03-26
HRP20020468B1 (en) 2009-02-28
PT1237878E (pt) 2007-06-18
ES2282162T3 (es) 2007-10-16
EP1237878B1 (en) 2007-03-21
EP1237878A2 (en) 2002-09-11
CA2392570C (en) 2010-05-11
RU2002117422A (ru) 2004-03-10
MY126972A (en) 2006-11-30
KR20020063906A (ko) 2002-08-05
WO2001042225A8 (en) 2002-06-06
NO20022633D0 (no) 2002-06-04
SI1237878T1 (sl) 2007-08-31

Similar Documents

Publication Publication Date Title
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
EG24361A (en) 4-pyrimiding1-n-acy1.l.phenlalanines
ZA200200477B (en) 2-pyrazolin-5-ones.
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
ZA200201055B (en) Amino-triazolopyridine derivatives.
ZA200202537B (en) Pour-on-formulations.
ZA200201829B (en) New phenylpiperazines.
ZA200109595B (en) 13-methyl-erythromycin derivatives.
ZA200203762B (en) 4-pyridinyl-IN-acyl-L-phenylalanines.
ZA200201276B (en) 3-Amino-2-phenyl-propane derivatives.
MXPA02000261A (es) Aminoindanos novedosos.
ZA200108481B (en) 8A- and 9A-15-membered lactams.
GB0029720D0 (en) I.S machine7544232001
MXPA01011285A (es) Derivados de tio-oxindol.
ZA200204581B (en) Nitro-sulfobenzamides.
MXPA01013157A (es) Perfil.
ZA200005361B (en) Positioning arrangement.
ZA200007821B (en) Hidroponiese Plantproduksiestelsel.
ZA200001527B (en) De-sleeving.
ZA200007026B (en) Acart.
ZA200203458B (en) Diaryl-enynes.
GB9905060D0 (en) The saboteur
GB9915251D0 (en) The overguard
GB9917156D0 (en) The nite-owl
ZA200001002B (en) Inclusion complex.